Pretransplant desensitization of donor-specific anti-HLA antibodies with plasmapheresis and immunoglobulin produces equivalent outcomes to patients with no donor specific antibodies in haploidentical hematopoietic cell transplant.

Autor: Cochran HC; Department of Medicine, Division of Oncology, Washington University, St. Louis, MO, USA., Slade MJ; Bone Marrow Transplantation & Leukemia Section, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA., Liu C; Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA., Gao F; Division of Public Health Sciences, Section of Oncologic Biostatistics, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA., Godbole S; Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA., Pruitt A; Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA., De Togni E; Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA., Grossman B; Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA., Abboud R; Department of Medicine, Division of Oncology, Washington University, St. Louis, MO, USA.

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2024 Dec; Vol. 65 (12), pp. 1811-1819. Date of Electronic Publication: 2024 Jul 11.

A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myeloma.

Autor: Goldsmith SR; Division of Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, MO, USA.; Division of Multiple Myeloma, Department of Hematology & Hematopoietic Transplantation, City of Hope, Duarte, CA, USA., Slade MJ; Division of Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, MO, USA. sladem@wustl.edu., Fiala M; Division of Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, MO, USA., Harding M; Division of Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, MO, USA., Crees ZD; Division of Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, MO, USA., Schroeder MA; Division of Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, MO, USA., Stockerl-Goldstein K; Division of Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, MO, USA., Vij R; Division of Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, MO, USA.

Publikováno v: Annals of hematology [Ann Hematol] 2024 Nov; Vol. 103 (11), pp. 4557-4565. Date of Electronic Publication: 2024 Sep 04.

Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone.

Autor: Loncharich AJ; Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO. Electronic address: a.j.loncharich@wustl.edu., Fiala MA; Division of Oncology, Washington University School of Medicine, St. Louis, MO., Slade MJ; Division of Hematology & Oncology, Washington University School of Medicine, St. Louis, MO., Vickroy A; Division of Oncology, Washington University School of Medicine, St. Louis, MO., Kavanaugh M; Division of Oncology, Washington University School of Medicine, St. Louis, MO., Wilson C; Division of Oncology, Washington University School of Medicine, St. Louis, MO., Schroeder MA; Division of Oncology, Washington University School of Medicine, St. Louis, MO., Stockerl-Goldstein K; Division of Oncology, Washington University School of Medicine, St. Louis, MO., Vij R; Division of Oncology, Washington University School of Medicine, St. Louis, MO., Sanfilippo KM; Division of Hematology, Washington University School of Medicine, St. Louis, MO.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2023 Nov; Vol. 23 (11), pp. 825-828. Date of Electronic Publication: 2023 Jul 23.

Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.

Autor: Major A; The University of Chicago Comprehensive Cancer Center, Chicago, IL.; University of Colorado Cancer Center, Aurora, CO., Yu J; The University of Chicago Comprehensive Cancer Center, Chicago, IL., Shukla N; The University of Chicago Comprehensive Cancer Center, Chicago, IL., Che Y; The University of Chicago Comprehensive Cancer Center, Chicago, IL., Karrison TG; The University of Chicago Comprehensive Cancer Center, Chicago, IL., Treitman R; University of Colorado Cancer Center, Aurora, CO., Kamdar MK; University of Colorado Cancer Center, Aurora, CO., Haverkos BM; University of Colorado Cancer Center, Aurora, CO., Godfrey J; City of Hope Comprehensive Cancer Center, Duarte, CA., Babcook MA; The Ohio State University James Comprehensive Cancer Center, Columbus, OH., Voorhees TJ; The Ohio State University James Comprehensive Cancer Center, Columbus, OH., Carlson S; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA., Gaut D; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA., Oliai C; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA., Romancik JT; Winship Cancer Institute at Emory University, Atlanta, GA., Winter AM; Taussig Cancer Institute at Cleveland Clinic, Cleveland, OH., Hill BT; Taussig Cancer Institute at Cleveland Clinic, Cleveland, OH., Bansal R; Mayo Clinic Rochester, Rochester, MN., Villasboas Bisneto JC; Mayo Clinic Rochester, Rochester, MN., Nizamuddin IA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL., Karmali R; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL., Fitzgerald LA; Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT., Stephens DM; Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT., Pophali PA; University of Wisconsin Carbone Cancer Center, Madison, WI., Trabolsi A; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL., Schatz JH; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL., Hu M; Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Bachanova V; Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Slade MJ; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO., Singh N; Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO., Ahmed N; The University of Kansas Cancer Center, Kansas City, KS., McGuirk JP; The University of Kansas Cancer Center, Kansas City, KS., Bishop MR; The University of Chicago Comprehensive Cancer Center, Chicago, IL.; David and Etta Jonas Center for Cellular Therapy, The University of Chicago Medicine, Chicago, IL., Riedell PA; The University of Chicago Comprehensive Cancer Center, Chicago, IL.; David and Etta Jonas Center for Cellular Therapy, The University of Chicago Medicine, Chicago, IL., Kline J; The University of Chicago Comprehensive Cancer Center, Chicago, IL.; David and Etta Jonas Center for Cellular Therapy, The University of Chicago Medicine, Chicago, IL.

Publikováno v: Blood advances [Blood Adv] 2023 Aug 22; Vol. 7 (16), pp. 4528-4538.

The role of chemokines and interleukins in acute lymphoblastic leukemia: a systematic review.

Autor: Stajer, Martin^1,2, Horácek, Jan M.^1,2 jan.horacek@unob.cz, Kupsa, Tomás^1,2, Zák, Pavel²

Publikováno v: Journal of Applied Biomedicine. 2024, Vol. 22 Issue 4, p165-184. 20p.